Citadel Advisors’s Augmedix, Inc. Common Stock AUGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-19,600
Closed -$17.2K 15536
2024
Q2
$17.2K Sell
19,600
-4,200
-18% -$8.66K ﹤0.01% 12759
2024
Q1
$97.3K Buy
23,800
+16,700
+235% +$74.7K ﹤0.01% 11396
2023
Q4
$41.5K Sell
7,100
-13,600
-66% -$71.6K ﹤0.01% 11981
2023
Q3
$107K Buy
+20,700
New +$97.1K ﹤0.01% 10822

Other funds holding AUGX

Citadel Advisors's AUGX Position: Q3 2024 in Review

Citadel Advisors sold out of Augmedix, Inc. Common Stock (AUGX) in Q3 2024, closing a stake of 1,850,000 shares — an estimated $1.63M sold.

Citadel Advisors first reported a position in AUGX in Q4 2021 and held it in 8 quarters. The position peaked at $7.73M in Q1 2024. 45 funds tracked by Wall St. Rank hold AUGX as of Q3 2024.

  • Citadel Advisors reported no remaining Augmedix, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Citadel Advisors sold 1,850,000 Augmedix, Inc. Common Stock shares in Q3 2024, an estimated $1.63M.
  • Citadel Advisors first reported a position in Augmedix, Inc. Common Stock in Q4 2021 and held it in 8 quarters.
  • Citadel Advisors's Augmedix, Inc. Common Stock position peaked at $7.73M in Q1 2024.
  • 45 funds tracked by Wall St. Rank held Augmedix, Inc. Common Stock as of Q3 2024.

Based on Citadel Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.